Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • China,  Divisional Applications,  Inventions,  prosecution

    CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

    December 6, 2021

    In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even written about this China divisional patent strategy. However, a recent judgment decision has called this strategy into question. We share more about this interesting case below. Case Background A company in Zhejiang Province (JC Company) filed a divisional application with claims having a different scope of protection from its utility model “parent” (which was about…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • Biotech,  China,  Inventions,  Pharma,  prosecution

    CHINA: How Prohibiting “Illegal” Inventions Runs into Food Safety Law

    October 22, 2021

    Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its face, this provision seems extremely broad, undefined, and potentially very subjective. Whose moral standard? And how do you define “detrimental”? Because details of litigations are not always publicly available in China, we only have limited examples by which we can understand how Chinese courts and examiners interpret and apply this language. Below we highlight one…

    Read More
    eagleip No Comments

    Related Posts

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018

    No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

    November 23, 2018

    Diagnostic Claims in China

    January 9, 2020
  • China,  EIP Patent 101 Corner,  Inventions,  prosecution

    What is the difference between an Invention Patent and a Utility Model Patent?

    August 13, 2021

    There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate to shapes or structures of a product, and have a term of 10 years from the date of filing. Utility model applications are subject to preliminary examination to check for compliance with formal requirements, novelty, unity of invention and patentable subject matter. Invention patent applications are subject to search and examination similar to those conducted…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
 Older Posts
Newer Posts 

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard

Categories

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Aug 14, 2026 Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed
  • Jul 21, 2026 Connecting the Dots: China’s Evolving Standard for Numerical Sub-Range Amendments
  • Jul 14, 2026 Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics
  • Jun 25, 2026 No More Hindsight Bias: China’s Supreme People’s Court Reins in Patent Inventiveness Assessments
  • Jun 01, 2026 IP Update: China’s Supreme People’s Court Issues First Public Decision Defining China’s Inventorship Standard
  • May 22, 2026 Breaking: China Released Drug Trial Data Protection Implementation Measures
  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
© 2026 Eagle IP Limited
Savona Theme by Optima Themes